<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00734435</url>
  </required_header>
  <id_info>
    <org_study_id>OZ-101</org_study_id>
    <nct_id>NCT00734435</nct_id>
  </id_info>
  <brief_title>Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects</brief_title>
  <official_title>A Proof of Concept, Multi-Center, Randomized, Double-Blind, Parallel, Placebo-Controlled, Study of Zonisamide Sustained Release (SR) 360 mg Versus Placebo in the Prevention of Weight Gain Associated With Olanzapine Therapy for Psychosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orexigen Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orexigen Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if zonisamide SR will prevent weight gain in
      schizophrenic subjects who take olanzapine (Zyprexa)
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor Decision- Financial Considerations
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in total body weight</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <condition>Schizophreniform Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zonisamide SR 360 mg and olanzapine 10-20 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and olanzapine 10-20 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zonisamide SR plus olanzapine</intervention_name>
    <description>zonisamide SR 90 mg given twice daily and olanzapine 10 mg to 20 mg daily for 10 weeks (maintenance period)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo plus olanzapine</intervention_name>
    <description>Placebo given twice daily and olanzapine 10-20 mg for 10 weeks (maintenance period)</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects,18-55 years of age

          -  Outpatients diagnosed with schizophrenia, schizoaffective disorder, or
             schizophreniform disorder

          -  Body mass index (BMI) between 22-35 kg/m2 (inclusive)

          -  Negative serum pregnancy test in women of child-bearing potential

          -  If women of child-bearing potential, must be non-lactating and agree to use an
             acceptable form of contraception, which in all cases, includes one type of barrier
             method, throughout the study period and for 30 days after discontinuation of study
             drug

          -  Subject requires a change in antipsychotic treatment and olanzapine is deemed by the
             Investigator to be a reasonable antipsychotic treatment choice

          -  No clinically significant abnormality on ECG

          -  No clinically significant laboratory abnormality

          -  Negative urine drug screen

          -  Must be considered reliable and possess a level of understanding that enables the
             subject to provide written informed consent and to comply with protocol procedures and
             schedule

          -  Must be able to read and understand English

        Exclusion Criteria:

          -  Diagnosis of substance dependence within the 6 months prior to randomization

          -  diagnosis of substance abuse (except for nicotine and caffeine) within the 3 months
             prior to randomization

          -  Suicidal behavior or ideation within 3 months prior to randomization, or any current
             suicidal ideation or intent

          -  Presence of dementia or other organic brain syndrome

          -  Serious or unstable medical illnesses

          -  Known, uncorrected narrow-angle glaucoma

          -  Diagnosis of eating disorder as defined by DSM-IV within 6 months prior to
             randomization

          -  Require treatment with any typical or atypical antipsychotic in addition to olanzapine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Breier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Larue D. Carter Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammed Alam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>American Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerald Maguire, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCI Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zinoviy Benzar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brooklyn Medical Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammed Bari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Synergy Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tran Johnson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CNRI</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduard Gfeller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida Clinical Research Center, Maitland Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Cutler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida Clinical Research Center, Bradenton Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Riesenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Atlanta Center for Medical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Synergy Research</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCI Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNRI San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Clincal Research Center</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Clinical Research Center</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>34208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Medical Research</name>
      <address>
        <city>Oak Brook</city>
        <state>Illinois</state>
        <zip>60523</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Larue D. Carter Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooklyn Medical Institute</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2008</study_first_submitted>
  <study_first_submitted_qc>August 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2008</study_first_posted>
  <disposition_first_submitted>November 27, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>November 27, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 29, 2012</disposition_first_posted>
  <last_update_submitted>November 27, 2012</last_update_submitted>
  <last_update_submitted_qc>November 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>schizophreniform</keyword>
  <keyword>schizoaffective disorder</keyword>
  <keyword>Zyprexa</keyword>
  <keyword>olanzapine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Weight Gain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Zonisamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

